There are 2137 resources available
LBA12 - PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
Presenter: Erica Mayer
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
161O - Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib
Presenter: Monica Arnedos
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
360O - Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
Presenter: Michael Weller
Session: Proffered Paper - CNS tumours
Resources:
Abstract
Slides
Webcast
362O - Perifocal edema volume correlates with density of tumour-infiltrating cytotoxic T cells in newly diagnosed glioblastoma
Presenter: Maximilian Mair
Session: Proffered Paper - CNS tumours
Resources:
Abstract
Slides
Webcast
363O - Clinical characterization of a real-life cohort of 6001 patients with brain metastases from solid cancers treated between 1986-2020
Presenter: Ariane Steindl
Session: Proffered Paper - CNS tumours
Resources:
Abstract
Slides
Webcast
364O - Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
Presenter: Thomas John
Session: Proffered Paper - CNS tumours
Resources:
Abstract
Slides
Webcast
981O - Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) versus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC): A randomised phase III trial
Presenter: Ming Shi
Session: Proffered Paper - GI, non colorectal
Resources:
Abstract
Slides
Webcast
LBA65 - The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
Presenter: Daniel Renouf
Session: Proffered Paper - GI, non colorectal
Resources:
Abstract
Slides
Webcast
1525O - The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the prospective platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry
Presenter: Thorsten Götze
Session: Proffered Paper - GI, non colorectal
Resources:
Abstract
Slides
Webcast
361O - Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study
Presenter: Mario Caccese
Session: Proffered Paper - CNS tumours
Resources:
Abstract
Slides
Webcast